Portage Biotech’s PORT-7 Shines in Preclinical Mesothelioma Fight, Eyes Human Trials

March 28, 2025

DENVER, Colo., Mar 28, 2025 (247marketnews.com)- Portage Biotech (NASDAQ:PRTG) unveiled a breakthrough at the 2025 European Lung Cancer Congress (ELCC) in Paris. New preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, showcased jaw-dropping results against mesothelioma, a notoriously tough cancer. Presented by Dr. Luciano Mutti of Gruppo Italiano Mesotelioma e Oncologia Ambientale, the findings revealed single-agent tumor suppression and a stunning >90% tumor growth halt when paired with an anti-PD1 antibody in a murine model. Tumor analysis lit up with CD3 and CD45 immune cells storming in, hinting at a revved-up immune attack.

Mesothelioma’s grim outlook, limited options, and stubborn immune resistance, makes this a potential game-changer. The Portage announcement stated, “This is the first time a selective A2B inhibitor has shown antitumor muscle against mesothelioma.”

With a $5 billion oncology frontier in sight, Portage isn’t stopping there. They’re fast-tracking PORT-6, a potent A2A adenosine receptor blocker, in the ADPORT-601 trial, aiming to pair it with PORT-7. This duo, the first-ever combo of selective A2A and A2B antagonists in patients, targets a full shutdown of adenosine’s immune-dampening tricks in the tumor microenvironment.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (PRTG)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.